News coverage about IDEXX Laboratories (NASDAQ:IDXX) has trended somewhat positive on Monday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IDEXX Laboratories earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0666223981356 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

A number of research firms have commented on IDXX. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a report on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a report on Friday, October 6th. Finally, Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a report on Wednesday, August 23rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $173.67.

IDEXX Laboratories (NASDAQ:IDXX) traded down $0.87 during trading on Monday, reaching $159.70. 379,549 shares of the company’s stock were exchanged, compared to its average volume of 699,220. The firm has a market capitalization of $14,004.71, a P/E ratio of 54.06, a PEG ratio of 2.43 and a beta of 0.42. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48. IDEXX Laboratories has a 1 year low of $113.92 and a 1 year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The firm had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.62 earnings per share. research analysts predict that IDEXX Laboratories will post 3.24 EPS for the current year.

In other news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the completion of the transaction, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,000 shares of company stock valued at $16,686,200. 2.77% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/idexx-laboratories-idxx-receiving-somewhat-positive-news-coverage-accern-reports/1758117.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.